Loading…
← CockpitCompetitor Analysis › 2576.HK Zhejiang Taimei Medical Technology Co Ltd Class HOpen in the cockpit ↗

Zhejiang Taimei Medical Technology Co Ltd Class H2576.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Information Technology›Packaged Software
Momentum neutral 52
Mkt cap
$318M
US dollars, full cap
Free float
81%
of shares outstanding
$/day
$30,938
20-day average traded
Fwd P/E
34.2×
forward earnings
ROIC−WACC
-32.2 pp
WACC 5.6%
Hurdle
n/a
no reverse DCF
Next earnings
131 days
29 Mar 2027
Close · HKDHK$4.35
1D-1.8%
1W-2.0%
1M-3.8%
3M-20.9%
6M-4.2%
YTD+9.8%
1Y-1.8%
ATR %5.9%
52w lowhigh42.0% off high

What Zhejiang Taimei Medical Technology does

No business profile yet.

Zhejiang Taimei Medical Technology at a glance

Size Zhejiang Taimei Medical Technology (2576.HK) is a Hong Kong Information Technology company (Packaged Software) with a market value of $318M, the 869th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$4.35 on 18 Nov 2026.

Performance Over six months the shares fell 4.2%, against -16.7% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue fell 7.0% over the last twelve months (peer median +19.4%); the operating margin is -13.5% (peer median 7.4%).

Valuation It trades at 34.2× forward earnings against a peer median of 22.1× (2nd most expensive of 12).

Capital Return on invested capital runs 32.2 points below its cost of capital (5.6% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 20262576.HK 97Peer median 85
Six months, rebased to 100: Zhejiang Taimei Medical Technology against the median of its 20 peers (local-currency closes).

Zhejiang Taimei Medical Technology financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$594MHK$556MHK$598MHK$633MHK$639M
Revenue growth—-7%-6%-1%—
Gross profitHK$255MHK$220MHK$211MHK$152MHK$159M
EBITDA-HK$59.1M-HK$56.3M-HK$221M-HK$373M-HK$513M
Net income-HK$73.4M-HK$46.5M-HK$233M-HK$383M-HK$480M
Free cash flown/aHK$1.91M-HK$192M-HK$365M-HK$385M
Capital expendituren/aHK$4.09MHK$6.16MHK$10.5MHK$32.8M
Total debtn/aHK$68.1MHK$37.0MHK$16.6MHK$51.5M

Quarterly statements and history in the cockpit →

Zhejiang Taimei Medical Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%490470CVXEMUDHRANET300930CRNC2660EGHTALBFR603189ASURSF301159369268820137634419300235425977812576.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang Taimei Medical Technology is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%10×20×30×40×EMUDHRANETCRNCEGHTALBFRASURSF6882013763441942592576.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang Taimei Medical Technology is the large dot.

Zhejiang Taimei Medical Technology competitors and peer comparison

How Zhejiang Taimei Medical Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang Taimei Medical Technology against its 20 peers (data as of 18 Nov 2026)
Measure2576.HKPeer medianRank in peer set
1-month return-3.8%-13.7%6th highest of 21
6-month return-4.2%-16.7%7th highest of 21
Distance from 52-week high-42.0%-46.7%10th highest of 21
Revenue growth (TTM)-7.0%+19.4%4th lowest of 21
Operating margin-13.5%7.4%3rd lowest of 20
Forward P/E34.2×22.1×2nd most expensive of 12
ROIC minus cost of capital-32.2 pp-3.2 pp3rd lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zhejiang Taimei Medical Technology 2576.HKHong Kong$318M-4%-7%-14%34.2×n/an/a
SemiFive 490470.KSSouth Korea$319M-65%+50%-22%n/an/an/a
Carvolix CVX.PAFrance$319M+52%-100%n/an/an/an/a
eMudhra EMUDHRA.NSIndia$318M-23%+30%18%22.4×n/an/a
Netcall NET.LUnited Kingdom$317M+13%+20%10%27.3×10.8%+16.3%
Hangzhou Yitong New Materials 300930.SZChina$317M-34%+51%7%n/an/an/a
Cerence CRNCUnited States$316M-24%+26%12%9.2×3.5%-5.3%
Zengame Technology 2660.HKHong Kong$321M-7%+19%24%n/an/an/a
8x8 EGHTUnited States$315M-4%+4%4%5.8×10.0%+6.7%
Sidetrade ALBFR.PAFrance$314M+18%+13%5%30.0×33.8%+16.1%
Shanghai WonderTek Software 603189.SSChina$314M-42%+43%-7%n/an/an/a
Asure Software ASURUnited States$313M+19%+21%1%9.7×43.9%+16.5%
Stillfront SF.STSweden$313M+15%-12%16%4.2×-15.4%+7.4%
Beijing SunwayWorld Science & Technology 301159.SZChina$313M-30%+18%4%n/a40.3%+7.0%
FFRI Security 3692.TJapan$324M-7%+15%28%n/a32.8%+21.9%
Beijing Infosec Technologies 688201.SSChina$311M-25%+1%-3%38.4×47.8%+5.5%
Pro-Ship 3763.TJapan$327M+12%+16%36%17.2×-7.5%+9.4%
Finatext 4419.TJapan$327M-10%+45%16%22.1×n/an/a
Shenzhen Fangzhi Science and Technology 300235.SZChina$327M-37%+27%7%n/an/an/a
ExaWizards 4259.TJapan$308M-45%+34%11%25.1×36.9%+35.6%
TPIsoftware 7781.TWOTaiwan$330M-39%-16%-32%n/an/an/a

Questions

Which companies are Zhejiang Taimei Medical Technology's closest peers?
The cockpit's peer set: SemiFive (490470.KS), Carvolix (CVX.PA), eMudhra (EMUDHRA.NS), Netcall (NET.L), Hangzhou Yitong New Materials (300930.SZ), Cerence (CRNC), Zengame Technology (2660.HK), 8x8 (EGHT).
Is Zhejiang Taimei Medical Technology expensive compared with its peers?
On forward p/e it trades at 34.2× against a peer median of 22.1×, 2nd most expensive of 12 in its peer set.
How has Zhejiang Taimei Medical Technology stock performed?
Over six months to 18 Nov 2026 the shares returned -4.2% against -16.7% for the median peer; over one year -1.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.